

Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults

WHO Library Cataloguing-in-Publication Data

Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults.

1.HIV Infections – complications. 2.Skin Diseases – therapy. 3.AIDS-Related Opportunistic Infections. 4.Guideline. 5.Child. 6.Adult. I.World Health Organization.

ISBN 978 92 4 154891 5

(NLM classification: WC 503.5)

© **World Health Organization 2014**

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Switzerland

Contents

Abbreviations and acronyms	vii
Definitions of key terms	ix
Acknowledgements	xii
Executive summary	1
Summary of recommendations	3
1. Introduction	7
1.1 Background and context	7
1.2 Rationale for new guidelines	7
1.3 Why guidelines are needed	7
1.4 Objectives	9
1.5 Target audience	9
1.6 Scope of guidelines: which skin conditions to address?	10
1.7 Methodology	10
1.8 Review and update of recommendations	13
2. Tool to aid in diagnosis of skin conditions	14
3. Guiding principles for HIV testing, ART initiation and general care	15
4. Evidence and recommendations on Kaposi sarcoma	16
4.1. Background	16
4.2 Recommendations	18
4.3 Review question and summary of evidence	19
4.4 Rationale for recommendations	22
4.5 Other considerations for implementation and in choice of chemotherapy regimen	23
4.6 Research gaps	26
5. Evidence and recommendations on seborrhoeic dermatitis	27
5.1 Background	27
5.2 Recommendations	28
5.3 Review question and summary of evidence	28
5.4 Rationale for recommendations	29
5.5 Research gaps	30

6. Evidence and recommendations on papular pruritic eruption	31
6.1 Background	31
6.2 Recommendations	32
6.3 Review question and summary of evidence	32
6.4 Considerations for development of recommendations	33
6.5 Research gaps	34
7. Evidence and recommendations on eosinophilic folliculitis	35
7.1 Background	35
7.2 Recommendations	36
7.3 Review question and summary of evidence	36
7.4 Rationale for recommendations	37
7.5 Research gaps	39
8. Evidence and recommendations on tinea infections	40
8.1 Background	40
8.2 Recommendations	41
8.3 Review question and summary of evidence	41
8.4 Rationale for recommendations	42
8.5 Research gaps	43
9. Evidence and recommendations on herpes zoster	44
9.1 Background	44
9.2 Recommendations	44
9.3 Review question and summary of evidence	45
9.4 Rationale for recommendations	46
9.5 Research gaps	46
10. Evidence and recommendations on scabies	47
10.1 Background	47
10.2 Recommendations	48
10.3 Review question and summary of evidence	49
10.4 Rationale for recommendations	50
10.5 Research gaps	51
11. Evidence and recommendations on molluscum contagiosum	52
11.1 Background	52
11.2 Recommendations	52
11.3 Review question and summary of evidence	53
11.4 Rationale for recommendations	53
11.5 Research gaps	54

12. Evidence and recommendations on oropharyngeal candidiasis	55
12.1 Background	55
12.2 Recommendations	56
12.3 Review question and summary of evidence	56
12.4 Rationale for recommendations	58
12.5 Research gaps	58
13. Evidence and recommendations on Stevens-Johnson syndrome and toxic epidermal necrolysis	59
13.1 Background	59
13.2 Recommendations	60
13.3 Review question and summary of evidence	60
13.4 Rationale for recommendations	61
13.5 Research gaps	62
14. Dissemination, implementation and monitoring of these guidelines	63
14.1 Guidelines dissemination	63
14.2 Guidelines implementation	63
14.3 Monitoring and evaluating guidelines implementation	64
References	66
General	66
Kaposi sarcoma	67
Seborrhoeic dermatitis	69
Papular pruritic eruption	70
Eosinophilic folliculitis	71
Tinea infections	73
Herpes zoster	73
Scabies	74
Molluscum contagiosum	75
Oropharyngeal candidiasis	76
Stevens-Johnson syndrome/toxic epidermal necrolysis	78
Annexes	
Annex 1 Antiretroviral treatment recommendations	79
Annex 2 Drug interactions	84
Annex 3 Drug treatment regimens, dosages and costs	85
Web appendices (available on http://www.who.int/maternal_child_adolescent/documents/guidelines/en/)	
Appendix 1 GRADE tables	
Appendix 2 Tool to aid in diagnosis of skin conditions	

Abbreviations and acronyms

3TC	lamivudine
ABV	vinicristine with bleomycin and doxorubicin
ACTG	AIDS Clinical Trials Group
AIDS	acquired immunodeficiency syndrome
ART	antiretroviral therapy
BSA	body surface area
BV	bleomycin with vincristine
CI	confidence interval
EFV	efavirenz
FTC	emtricitabine
GDG	Guidelines Development Group
GRADE	grading of recommendations, assessment, development and evaluation
GRC	Guidelines Review Committee
HAART	highly-active antiretroviral therapy
HHV-8	human herpesvirus-8
HIV	human immunodeficiency virus
HR	hazard ratio
IRIS	immune reconstitution inflammatory syndrome
IV	intravenous fluids
IVIG	intravenous immunoglobulin
kg	kilogram
KOH	potassium hydroxide
KS	Kaposi sarcoma
m2	metre
MC	molluscum contagiosum
MCA	Department of Maternal, Newborn, Child and Adolescent Health
MD	mean difference
µg	microgram
mg	milligram
mm	millimetre
NNRTI	non-nucleoside reverse transcriptase inhibitor
OC	oropharyngeal candidiasis
OI	opportunistic infection
PI	protease inhibitor
PICO	Population, Intervention, Comparator, and Outcomes
PLD	pegylated liposomal doxorubicin
PPE	papular pruritic eruption

PUVA	psoralen combined with ultraviolet A
RCT	randomized controlled trial
RR	relative risk
SD	seborrhoeic dermatitis
SJS	Stevens-Johnson syndrome
TB	tuberculosis
TDF	tenofovir disoproxil fumarate
TEN	toxic epidermal necrolysis
TIS	tumour-immune system-systemic illness
UNAIDS	Joint United Nations Programme on HIV/AIDS
USA	United States of America
UVB	ultraviolet light – B (PUVA) therapy
VZV	varicella zoster virus
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27937

